(Q40713319)

23 September 2017

1 reference

title

Salmeterol: an inhaled beta 2-agonist with prolonged duration of action (English)

1 reference

23 September 2017

1

1 reference

23 September 2017

N Svedmyr

2

1 reference

23 September 2017

1 January 1993

1 reference

23 September 2017

1 reference

23 September 2017

171

1 reference

23 September 2017

5

1 reference

23 September 2017

249-264

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03215869

23 September 2017

0 references

cites work

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Risks versus benefits of inhaled beta 2-agonists in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Regular inhaled beta-agonist treatment in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Twelve months, treatment with inhaled salmeterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03215869

Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma

21 January 2018

1 reference

12 December 2020

Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

1 reference

12 December 2020

Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects

1 reference

12 December 2020

Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma

1 reference

12 December 2020

A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group

1 reference

12 December 2020

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

1 reference

12 December 2020

Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline

1 reference

12 December 2020

Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. French Multicentre Study Group

1 reference

12 December 2020

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

12 December 2020

Selectivity of beta-adrenoceptor agonists and antagonists in asthmatics

1 reference

12 December 2020

Formoterol, a new long-acting bronchodilator for inhalation

1 reference

12 December 2020

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

12 December 2020

Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine

1 reference

12 December 2020

Protection against allergen-induced asthma by salmeterol

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03215869

1 reference

23 September 2017

1 reference

PubMed ID

8105155